Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

July 3, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search